Correlation Between Puma Biotechnology and Cardio Diagnostics
Can any of the company-specific risk be diversified away by investing in both Puma Biotechnology and Cardio Diagnostics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Puma Biotechnology and Cardio Diagnostics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Puma Biotechnology and Cardio Diagnostics Holdings, you can compare the effects of market volatilities on Puma Biotechnology and Cardio Diagnostics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Puma Biotechnology with a short position of Cardio Diagnostics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Puma Biotechnology and Cardio Diagnostics.
Diversification Opportunities for Puma Biotechnology and Cardio Diagnostics
0.31 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Puma and Cardio is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Puma Biotechnology and Cardio Diagnostics Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cardio Diagnostics and Puma Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Puma Biotechnology are associated (or correlated) with Cardio Diagnostics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cardio Diagnostics has no effect on the direction of Puma Biotechnology i.e., Puma Biotechnology and Cardio Diagnostics go up and down completely randomly.
Pair Corralation between Puma Biotechnology and Cardio Diagnostics
Given the investment horizon of 90 days Puma Biotechnology is expected to under-perform the Cardio Diagnostics. But the stock apears to be less risky and, when comparing its historical volatility, Puma Biotechnology is 20.04 times less risky than Cardio Diagnostics. The stock trades about 0.0 of its potential returns per unit of risk. The Cardio Diagnostics Holdings is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest 17.00 in Cardio Diagnostics Holdings on September 14, 2024 and sell it today you would lose (7.58) from holding Cardio Diagnostics Holdings or give up 44.59% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 85.54% |
| Values | Daily Returns |
Puma Biotechnology vs. Cardio Diagnostics Holdings
Performance |
| Timeline |
| Puma Biotechnology |
| Cardio Diagnostics |
Puma Biotechnology and Cardio Diagnostics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Puma Biotechnology and Cardio Diagnostics
The main advantage of trading using opposite Puma Biotechnology and Cardio Diagnostics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Puma Biotechnology position performs unexpectedly, Cardio Diagnostics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will offset losses from the drop in Cardio Diagnostics' long position.| Puma Biotechnology vs. Ultragenyx | Puma Biotechnology vs. Crinetics Pharmaceuticals | Puma Biotechnology vs. Arvinas | Puma Biotechnology vs. Revolution Medicines |
| Cardio Diagnostics vs. Cardio Diagnostics Holdings | Cardio Diagnostics vs. Revelation Biosciences | Cardio Diagnostics vs. LMF Acquisition Opportunities | Cardio Diagnostics vs. OmniAb Inc |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Complementary Tools
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |